RA
VTAK icon

Royce & Associates’s Catheter Precision VTAK Stock Holding History

Royce & Associates’s Portfolio VTAK Stock Details VTAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$1.48M – 1052
2021
Q1 		$1.48M Buy
33
+12
+57% +$784K 0.01% 799
2020
Q4 		$1.51M Buy
21
+19
+950% +$1.13M 0.01% 768
2020
Q3 		$147K Hold
2
– – ﹤0.01% 951
2020
Q2 		$250K Hold
2
– – ﹤0.01% 920
2020
Q1 		$440K Buy
2
+1
+100% +$387K 0.01% 843
2019
Q4 		$340K Hold
1
– – ﹤0.01% 929
2019
Q3 		$435K Hold
1
– – ﹤0.01% 910
2019
Q2 		$939K Buy
+1
New +$911K 0.01% 844

Other funds holding VTAK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates's VTAK Position: Q2 2021 in Review

Royce & Associates sold out of Catheter Precision (VTAK) in Q2 2021, closing a stake of 33 shares — an estimated $1.48M sold.

Royce & Associates first reported a position in VTAK in Q2 2019 and held it in 8 quarters. The position peaked at $1.51M in Q4 2020. 10 funds tracked by Wall St. Rank hold VTAK as of Q2 2021.

  • Royce & Associates reported no remaining Catheter Precision position as of Q2 2021 after selling out during the quarter.
  • Royce & Associates sold 33 Catheter Precision shares in Q2 2021, an estimated $1.48M.
  • Royce & Associates first reported a position in Catheter Precision in Q2 2019 and held it in 8 quarters.
  • Royce & Associates's Catheter Precision position peaked at $1.51M in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Catheter Precision as of Q2 2021.

Based on Royce & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.